Product Description
Thiamin is a water-soluble vitamin also known as vitamin B1. Its biologically active form, thiamin pyrophosphate (TPP), is a cofactor in macronutrient metabolism. In addition to its coenzyme roles, TPP plays a role in nerve structure and function as well as brain metabolism. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/25564426/)
Mechanisms of Action: RTI Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Vitamin D Deficiency | Vitamin D Deficiency | Vitamin D Deficiency
Known Adverse Events: Diplopia | Dizziness | Headache | Erythema | Pruritus | Anaphylaxis | Angioedema | Urticaria | Edema
Company: Daewoong
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Korea, Spain
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: Cardiac Arrest|Huntington Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| HUNTIAM | P2 |
Unknown Status |
Huntington Disease |
2025-12-31 |
|
| STAR trial | P2 |
Recruiting |
Cardiac Arrest |
2024-11-30 |